Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation

Neuro-Oncology Practice

Volumn 3, Issue 4, 2016, Pages 281-289

  Morris, Katrina A ^a,b   Golding, John F ^c,d   Axon, Patrick R ^e   Afridi, Shazia ^f   Blesing, Claire ^g   Ferner, Rosalie E ^c,d,g   Halliday, Dorothy ^g   Jena, Raj ^h   Pretorius, Pieter M ^g   Gareth Evans, D ⁱ   McCabe, Martin G ⁱ   Parry, Allyson ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WESTMINSTER   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bevacizumab; Neurofibromatosis type 2; Schwannoma; Vestibular schwannoma

Indexed keywords

BEVACIZUMAB;

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; AUDIOLOGY; AUDITORY BRAIN STEM IMPLANT; CHILD; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; EPISTAXIS; FATIGUE; FEMALE; GENE DELETION; GENE MUTATION; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MENSTRUAL IRREGULARITY; NAUSEA; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL MUCOSITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PSYCHOSIS; QUALITY OF LIFE; RASH; SIDE EFFECT; TUMOR GROWTH; TUMOR VOLUME; URINARY TRACT INFECTION; WOUND HEALING IMPAIRMENT;

EID: 84989871139     PISSN: 20542577     EISSN: 20542585     Source Type: Journal    
DOI: 10.1093/nop/npv065     Document Type: Article

References (24)

1. Lloyd SK, Evans DG. Neurofibromatosis type 2 (NF2): diagnosis and management. Handb Clin Neurol. 2013;115:957-967.
2. Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71(4): 715-723.
3. Wilding A, Ingham SL, Lalloo F, et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet. 2012;49(4):264-269.
4. Dirks MS, Butman JA, Kim HJ, et al. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg. 2012;117(1):109-117.
5. Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. J Neurosurg. 2002;96(2):223-228.
6. Peyre M, Goutagny S, Bah A, et al. Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery. 2013; 72(6):907-913; discussion 914; quiz 914.
7. Baser ME, Mautner VF, Parry DM, Evans DG. Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. J Med Genet. 2005;42(12):903-906.
8. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al., Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.
9. Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046-1052.
10. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 2010;12(1):14-18.
11. Alanin MC, Klausen C, Caye-Thomasen P, et al. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol. 2015;272:3627-3633.
12. Hawasli AH, Rubin JB, Tran DD, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013;74(3): 136-141.
13. Blakeley J. Initial results of the phase 2 study of bevacizumab in children and adults with neurofibromatosis type 2 and symptomatic vestibular schwannomas. Paper presented at: 2013 NF conference (Children's Tumour Foundation); June 8-11, 2013; Monterey, CA.
14. Shepard TH, Tucci DL, Grant GA, Kaylie DM. Management of hearing in pediatric NF2. Otol Neurotol. 2012;33(6):1066-1070.
15. Hochart A, Gaillard V, Baroncini M, et al. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol. 2015;124(2): 229-236.
16. Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013;81(21 suppl 1):S33-S40.
17. Kramer S. Table 7-3 Critical Difference Values for PBWords based on the Binomial Distribution. In: Audiology: Science to Practice. 2nd ed. San Diego, CA: Plural Publishing; 2014.
18. Hornigold RE, Golding JF, Ferner RE, Ferner RE. Neurofibromatosis 2: a novel risk factor for hypertension? American Journal of Medical Genetics. Part A. 2011;155A(7):1721-1722.
19. Ferner RE, Shaw A, Evans DG, et al. Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol. 2014; 261(5):963-969.
20. U.S. Department of Human Health Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published 2010. http://evs.nci. nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7. pdf. Accessed January 12, 2015.
21. Hexter A, Jones A, Joe H, et al. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet. 2015;52:699-705.
22. Blakeley JO, Evans DG, Adler J, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012;158A(1): 24-41.
23. Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309-1316.
24. Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014;73(6): 1197-1204.